Study compares soft tissue sarcoma rates among U.S. military servicemen and men in the general population

A recent analysis reveals that the incidence rates of soft tissue sarcomas—cancers in muscle, fat, blood vessels, nerves, and tendons—are lower in young U.S. active-duty military servicemen compared with those in the general population, but higher in middle-aged servicemen, perhaps due to greater cumulative exposure to toxins. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Soft tissue sarcomas are rare cancers arising all over the body, in various organs and tissues such as muscle, fat, and viscera. Most sarcomas arise sporadically, but a small subset arise from exposure to radiation or other environmental factors.

Because individuals in the military may experience more frequent and greater exposure to such environmental risk factors, researchers compared incidence rates of soft tissue sarcomas between active-duty U.S. servicemen and men in the general U.S. population, with the goal of assessing whether they differed in the occurrence of soft tissue sarcoma, providing clues for future research on related factors. Due to small numbers of active servicewomen in the dataset for further analysis, a comparable evaluation could not be accurately performed in women.

After analyzing data from the Department of Defense’s Automated Central Tumor Registry (ACTUR) for active-duty servicemen and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program for men in the general population, soft tissue sarcoma incidence rates for men aged 18–59 years were lower in ACTUR than SEER: 14% lower overall, 22% lower among 18–39-year-olds, 15% lower among white men, and 23% lower among Black men, compared with their corresponding counterparts in the general population. Rates of soft tissue sarcomas that had spread or metastasized were also lower in ACTUR than in SEER. However, rates of soft tissue sarcomas were higher in ACTUR than in SEER for men aged 40–59 years, especially for localized tumors.

The scientists suggest that lower rates among young servicemen may be due to better health and early detection and treatment of cancer-associated conditions within the military health system that provides universal care. Higher rates among older servicemen, especially for localized tumors, may result from greater cumulative military-related exposures to toxins or earlier diagnosis of the cancer due to universal care, compared with the U.S. general population.

“Our study is descriptive, hoping to provide clues for analytical studies on factors associated with the differences between the military and general populations,” said senior author Kangmin Zhu, MD, PhD, of the Uniformed Services University of the Health Sciences. “Further descriptive research with more recent data containing a larger number of military patients is warranted.”

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com 

Full Citation:
“Incidence Rates of Soft Tissue Sarcoma among U.S. Military Servicemen: Comparison with the Rates in the General U.S. Population.” Julie A. Bytnar, Ashley B. Anderson, Benjamin K. Potter, Craig D. Shriver, and Kangmin Zhu. CANCER; Published Online: December 9, 2024 (DOI: 10.1002/cncr.35607).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.35607

Author Contact: Sharon K. Holland, Deputy Vice President for External Affairs at the Uniformed Services University of the Health Sciences, at sharon.holland@usuhs.edu

About the Journal     
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley
Wiley is one of the world’s largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today’s biggest obstacles into tomorrow’s brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.